ZZZijun Zhen

Zijun Zhen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zijun Zhen has a total of 157 co-authors. Here are the top co-authors by number of shared publications:

  • Juan Wang

    Department of Pediatric Oncology Sun Yat‐Sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine Guangzhou China

    26 shared publications
  • Junting Huang

    Department of Pediatric Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, PR China

    19 shared publications
  • Suying Lu

    Department of Pediatric Oncology Sun Yat‐Sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine Guangzhou China

    18 shared publications
  • Feifei Sun

    Department of Pediatric Oncology Sun Yat‐Sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine Guangzhou China

    15 shared publications
  • Jia Zhu

    Department of Pediatric Oncology Sun Yat‐Sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine Guangzhou China

    15 shared publications
  • Xiaofei Sun

    State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People’s Republic of China

    15 shared publications

Latest Publications

  • Targeted Therapy and Oral Chemotherapy as Maintenance Treatment in Pediatric Very‐High‐Risk and High‐Risk Rhabdomyosarcoma: A Retrospective Study of Efficacy and Safety

    by Lei Mao, Yumiao Mai, Suying Lu, Feifei Sun, Juan Wang, Jia Zhu, Junting Huang, Mengjia Song, Yu Zhang, Zijun Zhen, et al.

    Maintenance therapy (MT) and targeted drugs have improved the survival of patients with high‐risk rhabdomyosarcoma (RMS) in clinical trials. However, there are limited data concerning targeted drugs and oral chemotherapy for MT in pediatric patients with very‐high‐risk (VHR) and high‐risk (HR) RMS. Here, we evaluated the safety and effectiveness of these regimens and aimed to identify circulating tumor DNA (ct‐DNA) markers associated with prognosis. We retrospectively retrieved data for 102 pediatric patients with VHR or HR RMS who underwent MT at Sun Yat‐sen University Cancer Center from January 2011 to March 2025 involving targeted drugs plus oral chemotherapy (subgroup 1); targeted drugs (subgroup 2); and oral chemotherapy (subgroup 3). Ct‐DNA markers were examined throughout treatment and at follow‐up. Subgroups 1 and 2 comprised 14 and seven VHR RMS patients, respectively, and subgroup 3 consisted of 39 VHR and 42 HR RMS patients. With a median follow‐up of 32 months, no significant differences among subgroups in duration of remission ( p = 0.56) or 2‐year event‐free survival ( p = 0.78) were observed. PAX–FOXO1 fusion ( p = 0.01), CDK4 mutation ( p = 0.02), and TP53 mutation ( p = 0.02) were independently associated with unfavorable duration of remission. No grade 3 or higher treatment‐related adverse events were observed. MT with targeted drugs shows comparable efficacy in VHR and HR pediatric RMS patients, with manageable adverse reactions. Longitudinal ct‐DNA testing could guide treatment decision‐making and prognostic stratification for these patients.

  • Causal relationship between aspirin use and age-related macular degeneration

    by Juanhua Zhu, Chenggong Zeng, Rongsui Tang, Weiwei Lu, Shasha Wang, Lijuan Huang, Zhen Xiong, Aijun Deng, Zijun Zhen, Rongyuan Chen, et al.

    Although increasing evidence suggests an association between aspirin use and age-related macular degeneration (AMD), the potential causal relationship between them remains controversial. This study aims to explore the causal genetic association and potential mediators between aspirin use and AMD using Mendelian randomisation (MR) analysis. A bidirectional, two-sample, two-step MR analysis was performed to assess the potential causal relationships among aspirin use, AMD, and possible mediators. Multivariable MR was additionally performed to estimate the direct effect of aspirin use on AMD after adjusting for mediators. Causal estimates were primarily derived using an inverse variance weighted method. Horizontal pleiotropy, heterogeneity, and stability were evaluated using the MR-Egger intercept test, Cochran's Q test, and leave-one-out analysis. An MR analysis revealed that aspirin use was associated with an increased risk of both early and dry AMD. A mediation analysis indicated that aspirin use is associated with a lower level of serum low-density lipoprotein cholesterol (LDL-C), an elevated serum apolipoprotein A1 (APOA1) concentration, and an increased risk of early and dry AMD. Multivariable MR analysis further showed that after adjusting for LDL-C and APOA1, the direct effect of aspirin on AMD was attenuated to non-significance. This study provides robust genetic evidence that aspirin use is associated with an increased risk of early and dry AMD, and demonstrates that this association is fully mediated by decreased serum LDL-C and increased serum APOA1 levels, with no evidence of a direct effect independent of these lipid pathways.

  • Open Access

    Mechanism by which SAHA regulates HLA-E expression via the endoplasmic reticulum stress-related PERK/ATF4/CHOP pathway in neuroblastoma

    by Zhuoran Li, Xi Zhen, Chenggong Zeng, Yan Mao, Zhiqing Wei, Zijun Zhen

    Background: Human leukocyte antigen E (HLA-E) plays a role in tumor immune escape and is associated with poor prognosis in neuroblastoma (NB). This study aimed to investigate the regulatory effect of suberoylanilide hydroxamic acid (SAHA) on HLA-E expression via the PERK/ATF4/CHOP pathway in NB. Methods: A high HLA-E expression model in NB cells was established by stimulation with interferon-gamma (IFN-γ). The effects of SAHA on NB cell proliferation and migration were evaluated. In addition, the influence of SAHA on the PERK/ATF4/CHOP signaling pathway and HLA-E expression at the mRNA and protein levels was analyzed. Bioinformatics analysis was performed using data from the TARGET and Gene Expression Omnibus (GEO; GSE85047) databases to identify prognostic genes associated with NB. Results: Stimulation with IFN-γ successfully induced high HLA-E expression in NB cells. SAHA significantly suppressed NB cell proliferation and migration and downregulated HLA-E expression at both the mRNA and protein levels. Analysis of the TARGET database revealed that the prognosis of patients with NB was closely related to the expression levels of endoplasmic reticulum stress (ERS)-related proteins, particularly PERK and HLA-E. This association was validated using the GEO dataset GSE85047. Moreover, SAHA inhibited the expression of ERS pathway proteins, including PERK and CHOP, in NB cell lines. Conclusion: This study demonstrated that SAHA downregulates HLA-E expression by inhibiting the PERK/ATF4/CHOP pathway, offering new insights into the regulation of tumor proliferation, migration, and immune evasion in NB.


  • Open Access

    Precision Medicine Program in Chinese Pediatric Patients With Sarcoma

    by Suying Lu, Yu Zhang, Weiling Zhang, Junting Huang, Chao Yang, Juan Wang, Ju Gao, Xia Guo, Xiuli Yuan, Senmin Chen, et al.

    PURPOSE: Molecular profiles of sarcomas in Chinese children remain unknown. The Chinese Pediatric Precision Oncology Group (CPPOG) is a prospective precision medicine program aimed at defining tumor molecular profiles in pediatric oncology patients across China, which aids diagnosis and treatment decisions. Herein, we report, to our knowledge, the first data from the CPPOG trial. METHODS: Panel sequencing (830-gene DNA panel and 395-gene RNA panel) was performed on 214 tumors from 210 patients with sarcoma from 11 centers, between April 2021 and January 2022 in China. This study was prospectively analyzed to characterize subtype-specific somatic alterations and pathways. Molecular features among subgroups concerning response to treatment and pathologic characteristics were also identified. RESULTS: Genomic profiling revealed molecular aberrations in the patients: 88.3% harbored at least one somatic or germline alteration; 51.4% carried gene fusions (including 37 novel fusion variants); 46.3% possessed actionable therapeutic targets; 9.5% exhibited germline variants; and 14.3% had modified diagnoses based on molecular findings. In this study, the most common genetic alterations were TP53 mutation and EWSR1-FLI1 fusion. The most common activated pathways were TP53, PI3K, and RTK-RAS in pediatric sarcomas. Anaplastic embryonal rhabdomyosarcomas had special molecular characteristics, with high TP53 , MYCN , and MYCL gene alteration frequencies. The mutation frequencies of TP53 and NRAS were notably higher in patients who had undergone disease progression, relapse, or metastasis. Moreover, MYC , MYCN , and MDM2 alterations were more frequent in tumors with mitotic figures >50/3 mm 2 . CONCLUSION: Our study reveals the preliminary molecular landscape of Chinese pediatric sarcomas, indicating that molecular changes may represent different therapeutic responses and pathologic characteristics may correlate with molecular characteristics, suggesting the need for panel sequencing for pediatric sarcoma.

  • Open Access

    Prognostic implication of serum levels of IL-6 and IL-10 in children and adolescents with aggressive mature B-cell non-Hodgkin lymphoma

    by Chenggong Zeng, Zhiqing Wei, Junting Huang, Jia Zhu, Feifei Sun, Juan Wang, Suying Lu, Yizhuo Zhang, Xiaofei Sun, Zijun Zhen

    Aggressive mature B-cell non-Hodgkin lymphoma (B-NHL) is the most common subtype of non-Hodgkin lymphoma in children and adolescents. However, little progr

  • Open Access

    Causal relationship between hypertension and cancer: a two‐sample bidirectional Mendelian randomization study

    by Chenggong Zeng, Juanhua Zhu, Yan Mao, Xi Zhen, Zhiqing Wei, Zijun Zhen

    Background: Evidence from observational studies suggests that the association between hypertension and cancer is controversial, likely due to confounding factors and reverse causality. This study employs Mendelian randomization (MR) to investigate the causal relationship between hypertension and various cancers. Methods: We conducted two‑sample bidirectional MR analyses using genetic variants associated with hypertension (484,598 participants) and 17 site-specific cancers from various genome-wide association studies (GWAS) including the GWAS Catalog, Integrative Epidemiology Unit OpenGWAS project, and FinnGen study. GWAS data on anti-hypertensive drugs prescription were used to explore potential mechanisms. The primary analysis employed the inverse variance weighted (IVW) method, supplemented by MR-Egger, weighted median, weighted mode, and simple mode methods. Heterogeneity and pleiotropy were assessed using Cochran’s Q, the MR-Egger intercept test, the MR pleiotropy residual sum and outlier test, leave-one-out analysis, funnel plots, and MR-Robust Adjusted Profile Score analysis. Genetic instruments were selected based on genome-wide significance (P−8), LD clumping (r210. Single nucleotide polymorphisms (SNPs) associated with confounders (smoking or alcohol consumption) and the outcome were removed using FastTraitR. Results: We identified a potential causal relationship between hypertension and a decreased risk of gastric cancer [odds ratio (OR) =0.615, 95% confidence interval (CI): 0.415–0.912, P=0.02] and colorectal cancer (OR =0.708, 95% CI: 0.516–0.971, P=0.03). MR estimates were consistent in East Asian populations (gastric cancer, OR =0.573, P=0.01; colorectal cancer, OR =0.466, P=0.001) and directionally similar in the FinnGen cohort. Reverse MR analysis indicated an inverse association of lymphoma with hypertension risk (OR =0.992, 95% CI: 0.985–1.000, P=0.044), whereas genetic predisposition to thyroid cancer was positively associated with hypertension (OR =1.008, 95% CI: 1.002–1.013, P=0.01). Further investigation identified inverse associations between gastric cancer risk and the use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs) (OR =0.834, PConclusions: Our MR analyses suggested that genetic predisposition to hypertension was associated with a reduced risk of gastric and colorectal cancer. This inverse relationship may be mediated by biological pathways that are targeted by antihypertensive drugs, highlighting a potential mechanistic link worthy of further clinical investigation.

  • Prognostic Value of Peripheral Blood Lymphocyte Subsets in Children and Adolescents With High‐Grade Mature B‐Cell Non‐Hodgkin Lymphoma: A Real‐World Outcomes Study

    by Chenggong Zeng, Zhiqing Wei, Junting Huang, Jia Zhu, Feifei Sun, Juan Wang, Suying Lu, Yizhuo Zhang, Xiaofei Sun, Zijun Zhen

    Background: Little progress has been made in determining prognostic factors for patients with high‐grade mature B‐cell non‐Hodgkin lymphoma (HG B‐NHL). Based on the important role of lymphocytes in cancer progression, this study aimed to explore the effect of peripheral blood lymphocytes on the prognosis of pediatric HG B‐NHL. Methods: Patients aged less than 18 years with newly diagnosed HG B‐NHL were enrolled. Peripheral blood lymphocyte subset levels were detected at diagnosis, and their optimal cutoff values were determined according to event‐free survival (EFS). Results: In total, 206 patients were enrolled. The 5‐year EFS and overall survival (OS) rates of the whole group were 92.1% ± 1.9% and 96.6% ± 1.3%, respectively. The 5‐year EFS rate was worse in patients with a low relative CD4 + T‐cell count (87.2% vs. 97.0%, p = 0.008), high relative CD8 + T‐cell count (79.1% vs. 93.4%, p = 0.03), low CD4/CD8 ratio (80.5% vs. 94.2%, p = 0.01), and low B‐cell count (80.0% vs. 93.4%, p = 0.02) at diagnosis than their counterparts. Cox multivariate analysis identified low relative CD4 + T‐cell (HR = 4.91) and B‐cell (HR = 3.87) counts at diagnosis as independent adverse prognostic factors. Patients with simultaneously low levels of CD4 + T and B cells had the worst outcomes in the entire cohort, with a 5‐year EFS rate of 60.0%. Conclusion: Low relative CD4 + T‐cell and B‐cell counts at diagnosis are associated with poor prognosis in children and adolescents with HG B‐NHL in the real world.

    • 14 December 2024
      • Vol. 45  (12) , 1098-1105
    Open Access

    [Impact of tumor lysis syndrome on the prognosis of pediatric mature B-cell lymphoma].

    by C G Zeng, Z Q Wei, J T Huang, J Zhu, F F Sun, J Wang, S Y Lu, Y Z Zhang, X F Sun, Z Z Zhen

    Objective: This study aimed to investigate the effect of tumor lysis syndrome (TLS) on the prognosis of children and adolescents with intermediate- or high-risk high-grade mature B-cell nonHodgkin lymphoma (HG B-NHL) . Methods: This study collected the clinical data and prognosis of 283 patients aged P612.7 μmol/L (n=40). Similarly, patients with serum phosphate of ≤1.89 mmol/L (n=58) demonstrated lower 5-year EFS [ (71.6±6.0) % vs 100%, P=0.02] and OS rates [ (74.8±5.8) % vs 100%, P=0.03] compared with those with phosphate of >1.89 mmol/L (n=18) . Conclusions: TLS is associated with poor prognosis in patients with HG B-NHL. Patients with lower serum uric acid and phosphate levels during TLS demonstrated worse prognoses, indicating their potential value in predicting prognosis and guiding stratified treatment.

  • Open Access

    Mechanism of Drug Resistance to First‐Line Chemotherapeutics Mediated by TXNDC17 in Neuroblastomas

    by Chenggong Zeng, Zhuoran Li, Zhiqing Wei, Tingting Chen, Juan Wang, Junting Huang, Feifei Sun, Jia Zhu, Suying Lu, Zijun Zhen

    Background: The prognosis of high‐risk neuroblastomas (NB) that are resistant to first‐line induction chemotherapy is relatively poor. This study explored the mechanism of resistance to first‐line chemotherapeutics mediated by TXNDC17 and its potential solutions in NB.Methods: The genetic and clinical data of patients with NB were obtained from the Therapeutically Applicable Research to Generate Effective Treatments dataset. TXNDC17 and BECN1 expressions in NB cells were up‐ and downregulated by transfection with plasmids and shRNA, respectively. Autophagy‐related proteins were detected by western blot. Cell viability was determined using cell proliferation and toxicity experiments. Apoptotic cells were detected using flow cytometry.Results: Overall, 1076 pediatric and adolescent patients with NB were enrolled in this study. The 10‐year overall survival (OS) rates and event‐free survival (EFS) rates for the patients with a mutation of BECN1 were 37.4 ± 9.1% and 34.5 ± 8.8%, respectively. For patients with a mutation of TXNDC17, the 10‐year OS and EFS were 41.4 ± 5.9% and 24.3 ± 5.1%, respectively, which were significantly lower than those in the unaltered group. The overexpression of BECN1 and TXNDC17 reduced NB sensitivity to cisplatin (DDP), etoposide (VP16), and cyclophosphamide (CTX). Autophagy mediated by BECN1 was regulated by TXNDC17, and this process was involved in the resistance to DDP, VP16, and CTX in NB. Suberoylanilide hydroxamic acid (SAHA) can enhance the sensitivity and apoptosis of NB cells to chemotherapeutics by inhibiting TXNDC17, ultimately decreasing autophagy‐mediated chemoresistance.Conclusions: Acquired resistance to first‐line chemotherapeutics was associated with autophagy mediated by BECN1 and regulated by TXNDC17, which can be reversed by SAHA.


  • Open Access

    Stratified Treatment in Pediatric Anaplastic Large Cell Lymphoma: Result of a Prospective Open-Label Multiple-Institution Study

    by Tingting Chen, Chenggong Zeng, Juan Wang, Feifei Sun, Junting Huang, Jia Zhu, Suying Lu, Ning Liao, Xiaohong Zhang, Zaisheng Chen, et al.

    Purpose The risk stratification of pediatric anaplastic large cell lymphoma (ALCL) has not been standardized. In this study, new risk factors were included to establish a new risk stratification system for ALCL, and its feasibility in clinical practice was explored.Materials and Methods On the basis of the non-Hodgkin’s lymphoma Berlin–Frankfurt–Munster 95 (NHL-BFM-95) protocol, patients with minimal disseminated disease (MDD), high-risk tumor site (multiple bone, skin, liver, and lung involvement), and small cell/lymphohistiocytic (SC/LH) pathological subtype were enrolled in risk stratification. Patients were treated with a modified NHL-BFM-95 protocol combined with an anaplastic lymphoma kinase inhibitor or vinblastine (VBL).Results A total of 136 patients were enrolled in this study. The median age was 8.8 years. The 3-year event-free survival (EFS) and overall survival of the entire cohort were 77.7% (95% confidence interval [CI], 69.0% to 83.9%) and 92.3% (95% CI, 86.1% to 95.8%), respectively. The 3-year EFS rates of low-risk group (R1), intermediate-risk group (R2), and high-risk group (R3) patients were 100%, 89.5% (95% CI, 76.5% to 95.5%), and 67.9% (95% CI, 55.4% to 77.6%), respectively. The prognosis of patients with MDD (+), stage IV cancer, SC/LH lymphoma, and high-risk sites was poor, and the 3-year EFS rates were 45.3% (95% CI, 68.6% to 19.0%), 65.7% (95% CI, 47.6% to 78.9%), 55.7% (95% CI, 26.2% to 77.5%), and 70.7% (95% CI, 48.6% to 84.6%), respectively. At the end of follow-up, one of the five patients who received maintenance therapy with VBL relapsed, and seven patients receiving anaplastic lymphoma kinase inhibitor maintenance therapy did not experience relapse.Conclusion This study has confirmed the poor prognostic of MDD (+), high-risk site and SC/LH, but patients with SC/LH lymphoma and MDD (+) at diagnosis still need to receive better treatment (ClinicalTrials.gov number, NCT03971305).